In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between ...

In response to the threats, European governments raced to strike deals. The UK secured a zero tariff arrangement in return ...

FDA has taken steps to embrace AI in 2025, announcing in December that it will be providing agency staff with agentic AI ...

Bristol-Myers Squibb Company is rated a Buy with solid rebound and robust free cash flow margins. Learn more about BMY stock ...

Few professionals have lived that reality as closely as Girish Gupta, who, during his tenure as Deputy Manager of Supply ...

This Christmas, let’s remember that medications have their place, but they are not the center of our hope. The gifts God gives us — family, faith, fellowship, laughter and the miracle of Christ’s ...

From an undead scientist to steamy romance to scented scarves, these pieces of work stimulated innovation. This year, MM+M ...

Dear Shareholders, 2025 has been a transformational year for Nasus Pharma. We’ve made considerable progress building a strong, focused company with significant clinical impact, by developing drug ...

Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...

We carry these mixed feelings into 2026, which is slated to be another great—yet perhaps troubled—year for science. No list ...

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.